Market Access/ News/ News/ News/ Oncology NICE green lights Roche’s Rozlytrek for NTRK tumours Phil Taylor Bayer, genomics, Oncology, Roche, Rozlytrek, Vitrakvi 0 Comment The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid Share X NICE green lights Roche’s Rozlytrek for NTRK tumours https://pharmaphorum.com/news/nice-green-lights-roches-rozlytrek-for-ntrk-tumours/
Market Access/ News/ News Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer Phil Taylor Bayer, Oncology, rare cancer, Roche, Rozlytrek, Vitrakvi 0 Comment The UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share X Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer https://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
News/ News/ Oncology Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU Phil Taylor Bayer, Oncology, Roche, Rozlytrek, Vitrakvi 0 Comment Bayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share X Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU https://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
Bayer, genomics, Oncology, Roche, Rozlytrek, Vitrakvi
0 Comment
